Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Phenex's PX-102 proves safe and well tolerated in phase I study

Nov. 2, 2012

Novel cannabinoid CB1 receptor antagonists synthesized by Korean group

Nov. 2, 2012

Korean scientists patent novel DPP IV inhibitors

Nov. 2, 2012

Semaphorin-3A demonstrates osteoprotective qualities and therapeutic potential

Oct. 31, 2012

Oral salmon calcitonin shows potential as antidiabetic therapy in vivo

Oct. 31, 2012

Takeda submits Japanese NDA for cetilistat

Oct. 31, 2012

E.U. approval for linagliptin as add-on therapy in type 2 diabetes

Oct. 30, 2012

ViaCyte receives grant to continue development of diabetes therapy

Oct. 30, 2012

FDA turns down request for appeal on NDA for vaginal gel in preterm birth

Oct. 29, 2012

New GPR119 receptor agonists disclosed by Arena Pharmaceuticals

Oct. 29, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Deerfield-backed Boulevard, Metis pen $1.6B trispecific TCE deal
BioWorld
A U.S. biotechnology company founded by Deerfield Management Company L.P. licensed exclusive rights to Metis Techbio Co. Ltd.’s preclinical trispecific T-cell...